ZSZefeng Shen

Zefeng Shen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zefeng Shen has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A HYBRID ENERGY‐ AND AI‐BASED SCREENING FOR NOVEL INHIBITORS OF LCK FOR THE TREATMENT OF T‐CELL LYMPHOBLASTIC LYMPHOMA

    by H. Guo, Z. Shen, H. Wang, J. Yang, Y. Liu, X. Liu, Q. Zhang, K. Zhou

  • The Efficacy and Safety of Additional Anti-HER2-Targeting Drugs in the Treatment of HER2-Positive Advanced Breast Cancer: A Meta-Analysis

    by Nannan Du, Bangsheng Chen, Zefeng Shen, Bin Zhou, Xiaojun Fu, Danyi Mao, Feiyan Mao, Derry M. Ng, Parikshit A. Khadaroo, Lei Yang

    Background: HER2-positive breast cancer patients account for one-fifth of the total breast cancer population. Besides, more and more anti-HER2-targeting drugs have appeared clinically. Objective: This study aimed to analyze the efficacy and safety of additional anti-HER2 (Human Epidermal growth Factor Receptor 2)-targeting drugs in the treatment of HER2-positive advanced breast cancers. Methods: The following databases were searched for published articles containing data on the efficacy and safety of additional anti-HER2- targeting drugs in HER2-positive advanced breast cancer from the time of their inception until December 2019: PubMed, Web of Science, EBSCO, and Cochrane library. The primary outcomes were progression-free survival (PFS) and overall survival(OS). Results: The additional anti-HER2-targeting drugs significantly improved the PFS (HR: 0.66, p<0.001) and OS (HR: 0.77, p<0.001) of HER2-positive advanced breast cancer patients. Regarding drug types, lapatinib was the most effective (HR: 0.53, 95% Cl: 0.39-0.67, p<.001), followed by pertuzumab (HR: 0.72, 95% Cl: 0.55-0.89, p=0.001). Trastuzumab was the least beneficial (HR: 0.87, 95% Cl: 0.31-1.44, p=0.594). Concerning treatment regimen, first-line treatment (HR: 0.67, 95% Cl: 0.52-0.82, p<0.001) was more effective than non-first-line treatment (HR: 0.82, 95% Cl: 0.71-0.94, p=0.004). The main Adverse Events (AEs) observed were diarrhea and decreased ejection fraction. Conclusion: Additional anti-HER2-targeting drugs can improve long-term prognosis in HER2-positive advanced breast cancers. Besides, they are associated with fewer AEs and are tolerable. Lapatinib is the most effective drug, followed by pertuzumab, whereas trastuzumab is the least effective. Concerning treatment, we recommend the use of anti-HER2-targeting drugs in first-line therapy of HER2-positive advanced breast cancers.

  • Open Access

    Prognostic factors in stage I gastric cancer: A retrospective analysis

    by Dingcheng Zheng, Bangsheng Chen, Zefeng Shen, Lihu Gu, Xianfa Wang, Xueqiang Ma, Ping Chen, Feiyan Mao, Zhiyan Wang

    Purpose: The purpose of this research is to investigate the prognostic factors of patients with stage I gastric cancer (GC) and to determine whether adjuvant chemotherapy improves the prognosis for high-risk patients. Methods: We performed a retrospective analysis at Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, and HwaMei Hospital, University of Chinese Academy of Sciences from January 2001 to December 2015. Cox regression and Kaplan-Meier were used to evaluate the relationship between the patients’ clinicopathologic characteristics and prognosis. Results: A total of 1,550 patients were eligible for the study. The 5-year disease-free survival (DFS) rate of all enrolled patients was 96.5%. The pT and pN stages were significantly associated with the prognosis. The 5-year DFS rates of the three subgroups (T1N0, T2N0, and T1N1) were 97.8%, 95.7%, and 90.5%, respectively (p < 0.001). In the T1N1 subgroup, patients not undergoing chemotherapy showed a lower 5-year DFS rate compared to those undergoing chemotherapy, although the difference was not statistically significant. Conclusions: Both the pT and pN stages were closely associated with the prognosis of patients with stage I GC. We also found that the danger coefficient of the pN stage was higher than that of the pT stage, and that postoperative adjuvant chemotherapy might be a reasonable approach to improve outcomes of high-risk patients, particularly in the T1N1 group.


  • Open Access

    Risk Factors for Duodenal Stump Leakage after Laparoscopic Gastrectomy for Gastric Cancer

    by Lihu Gu, Kang Zhang, Zefeng Shen, Xianfa Wang, Hepan Zhu, Junhai Pan, Xin Zhong, Parikshit Asutosh Khadaroo, Ping Chen

    Gu L, et al. J Gastric Cancer. 2019 Sep;20:e4. https://doi.org/10.5230/jgc.2020.20.e4